17 May 2010

Pronota raises an additional EUR 1.5 million in a final close of its Series B financing totaling EUR 7.9 million

Ghent, Belgium; 17th May 2010 - Pronota NV today announced that it has raised an additional EUR 1.5 million in the final close of its Series B financing. The financing has been subscribed by MedSciences Capital, the venture capital arm of Kempen & Co, which is a specialized Dutch merchant bank. Pronota has raised a total of EUR 7.9 million in its Series B round, which has been subscribed by premier life sciences investors such as Gimv, Biotech Fund Flanders, LSP, JJDC, KBC Private Equity, VIB, MP Healthcare Venture Management Inc., Baekeland Fund and MedSciences Capital. Pronota is using the proceeds of the Series B financing to push forward its diagnostic development programs in the cardio-renal area, pre-eclampsia, sepsis, and ovarian cancer.

The results obtained so far in its cardio-renal and other programs provide extensive validation of Pronota's technology. Pronota now addresses a range of significant commercial opportunities, and is aiming to have its first product ready for launch in 2012.

Notes to editors:

About Pronota

Pronota was founded in late 2004 to develop protein biomarker diagnostics derived from its proprietary platform that uniquely mines for low-abundance protein biomarkers in blood. In this short time, it has successfully implemented its technology and made substantial progress in its diagnostic product programs.

Further information is available at http://www.pronota.com.